Millions of patients worldwide suffer from macular edema and associated loss of visual acuity. Luckily, the range of available treatments has widened over the past few years including the dexamethasone sustained-release implant (Ozurdex®) - a biodegradable intravitreal implant that maintains a high concentration of corticosteroids in the vitreous for up to 3 - 4 months. This progressive release decreases treatment burden compared to anti-VEGF that often require monthly injections.

We present the results of 3 real-life studies investigating the effects of Ozurdex® in diabetic macular edema (RELDEX study), non-infectious uveitis (RUVDEX study) and persistent postsurgical macular edema (EPISODIC 2 study).

A known side effect of steroids is ocular hypertension. Real-life studies SAFODEX 1 and 2 report new data on pressure tolerance of Ozurdex® and identify risk factors for ocular hypertension after dexamethasone implant offering scientific proof for better patient selection and follow-up.